124
Report on Innovativeness of the Health Sector in Poland in 2012
US Pharmacia Sp. z o.o. Assessment with 5A System: NCCNN Place on the List of medical sector: 40 Place on the 500’2010 List: not listed
www.usp.pl Established in: 1995 Company size: medium Address: 50–507 Wrocław, ul. Ziębicka 40 Voivodship: Lower Silesian
488.2
481.7
715.0
519.8
06
07 08 09 10 Net sales data for the 2005–2010 period in mln PLN
Financial data (thousand PLN)
05
360.7
353.3
Type of business: pharmaceuticals Description of business activity: US Pharmacia Ltd. is the Polish company, which has set the trends in the market of medicines available over the counter (OTC) for more than 20 years. The company was established in the United States as US Pharmacia and now it is a group of some companies operating in the field of health care. The company is the leader of medicines available over the counter (OTC) in Poland. The company has its own laboratories and R&D department. In Wroclaw there is the manufacturing facility, which provides an average of more than 140 million individual packages per year. The main office is located in Warszawa. The company’s offer includes such medicines as Ibuprom, Apap, Gripex, Stoperan, Vigor, Verdin and Xenna. The company’s portfolio has over 100 products. Shareholders: Medvic S.A.R.L. (Luxembourg) – 100% 2005 Net sales revenues Net financial income (profit/loss)
2006
2007
2008
2009
2010
353 338.7 360 741.0 519 831.9 715 045.7 481 698.2 488 161.5 54 717.4 57 368.0 65 880.6 148 684.5 60 826.5 100 010.0
Capitalized value of R&D expenses
2 869.3
Intangible assets
49 766.4
317.4 2 392.7 11 350.6
8 709.8
Total assets
204 827.0 199 589.0 201 114.0 339 535.2 386 588.6 265 709.4
Equity
101 012.5 104 541.0 112 176.2 230 054.1 290 880.6 69 954.3
Description of innovative activity: According to the 5A methodology, the company US Pharmacia is characterized by a high assessment of process innovativeness level and a high assessment of investment in innovative activity. The company innovativeness assessment in the 5A system is NCCNN. Company status: investor in research and development
Voxel S.A. Assessment with 5A System: CCNNC Place on the List of medical sector: 45 Place on the 500’2010 List: not listed
www.voxel.pl Established in: 2005 Company size: small Address: 30–663 Kraków, ul. Wielicka 265 Voivodship: Lesser Poland
05
06
07 08 09 10 Net sales data for the 2005–2010 period in mln PLN
Financial data (thousand PLN)
36.6
14.6
31.3
Type of business: hospital services and medical care Description of business activity: Voxel Company JSC is one of the market leaders in Poland diagnostic imaging by offering a comprehensive range of services and products associated with the use of the latest technological advances in medicine. The company provides services in the field of diagnostic imaging and teleradiology outsourcing and provides IT systems for hospitals and diagnostic centers and deals with the implementation of projects fitting the diagnostic laboratory. The company brings together a unique team of medical imaging professionals with extensive clinical experience and recognized scientific achievements. By working closely with major suppliers of medical equipment, Voxel MCD labratories have modern equipment and provide specialized services at the highest level. Shareholders: Voxel International S.a r.l. – 53.16%, Ipopema TFI JSC – 17.07%, Others – 29.77% 2005 Net sales revenues Net financial income (profit/loss)
2006
2007
2008
2009
2010
14 589.8 31 325.3 36 634.7 373.5
2 601.9
49.7
1 146.1
1 221.8
Capitalized value of R&D expenses Intangible assets Total assets
47 484.9 57 231.4 148 429.1
Equity
24 711.4 27 288.8 68 127.9
Description of innovative activity: According to the 5A methodology, the company Voxel JSC is characterized by a high assessment of market and process innovativeness level and a high assessment of ability of obtaining the financing of innovative projects from the EU funds. The company innovativeness assessment in the 5A system is CCNNC. Company status: beneficiary of national programmes of the EU
raport med ANG karty przedsiębiorstw.indd 124
2012-10-10 18:10:20